Pasireotide (aspartate) |
| Catalog No.GC44571 |
Pasireotide is a somatostatin receptor (SSTR) agonist that binds selectively to SST1, SST2, SST3, and SST5 over SST4 (IC50s = 9.3, 1, 1.5, 0.16, and >100 nM, respectively, for human recombinant receptors).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 820232-50-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pasireotide is a somatostatin receptor (SSTR) agonist that binds selectively to SST1, SST2, SST3, and SST5 over SST4 (IC50s = 9.3, 1, 1.5, 0.16, and >100 nM, respectively, for human recombinant receptors). It dose-dependently inhibits growth hormone release stimulated by growth hormone-releasing hormone (GHRH) in primary rat anterior pituitary cells and inhibits adrenocorticotropic hormone (ACTH) secretion by some primary human corticotrope adenomas at a concentration of 10 nM. Pasireotide (10 nM) also inhibits ACTH release from and proliferation of mouse AtT20 pituitary corticotrope cells in vitro and inhibits tumor growth of subcutaneously implanted AtT20 cells in vivo in nude mice when administered at a dose of 1.5 μg per day. Pasireotide (0.03 mg/kg) decreases plasma ACTH concentrations and tumor size in dogs with ACTH-dependent Cushing's disease. Formulations containing pasireotide have been used in the treatment of acromegaly and Cushing's disease.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *